BRAF and melanoma: Considering that around half of melanomas harbour mutations in BRAF V600E, the first targeted therapies approved by the U.S. Food and Drug Administration (FDA) were vemurafenib and dabrafenib, followed by BRAF/MEK inhibitor pairing treatment [22].